Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells

Authors:
  • SWSandra Wissing
    Sandra Wissing
  • CBChristian Brandl
    Christian Brandl
  • NPNadja Prang
    Nadja Prang
  • RLRalf Lutterbuese
    Ralf Lutterbuese
  • AKAlex Kozhich
    Alex Kozhich
  • JSJoAnn Suzich
    JoAnn Suzich
  • MLMathias Locher
    Mathias Locher
  • PKPeter Kiener
    Peter Kiener
  • PKPeter Kufer
    Peter Kufer
  • RHRobert Hofmeister
    Robert Hofmeister
  • PBPatrick A. Baeuerle
    Patrick A. Baeuerle

Abstract
No abstract available

This publication has 27 references indexed in Scilit: